2.5 Residual Risk & Follow-Up Medical Plans
Key Takeaways
- Residual risk is the remaining probability of being a carrier or of an affected pregnancy after negative or uninformative testing, incorporating detection rate limits and untested variant types
- Negative carrier screening never implies zero risk when sensitivity is incomplete, not all genes were assayed, or family-specific variants may be missed by the method
- Follow-up plans pair residual numbers with actions: partner testing, expanded sequencing, targeted familial-variant testing, prenatal/preimplantation options, or phenotype-first evaluation
- When a familial pathogenic variant is known, test for that variant; a negative generic screening panel does not replace site-specific testing
- Document assumptions, detection rates, and recommended next steps so residual-risk counseling is clinically actionable and revisable when new results arrive
2.5 Residual Risk & Follow-Up Medical Plans
Quick Answer: After negative or uninformative results, quote a residual risk (not zero), explain why (detection rate, gene coverage, family-variant mismatch), and attach a follow-up plan: partner testing, expanded/gene-specific testing, site-specific familial testing, prenatal options, or clinical surveillance.
Domain 2A closes the loop from pedigree → Mendelian prior → Bayes → what we do next. A correct residual fraction without a plan is incomplete care and an incomplete exam answer.
What "Residual Risk" Means
Residual risk is the probability that remains after incorporating available negative evidence. Common forms:
| Residual target | Typical setting | Driven by |
|---|---|---|
| Residual carrier probability | Negative carrier screen | Prior × (1 − detection rate), normalized (Bayes) |
| Residual affected-pregnancy risk | Both partners screened or one known carrier | Carrier posteriors × 1/4 (AR) or XL transmission fractions |
| Residual inheritance risk | Negative test for a known familial variant | Lab error, rare sample mix-up, or unrecognized alternate molecular mechanism—usually very low if the assay covers the variant |
| Residual syndromic risk | Uninformative panel/exome | Phenotypic differential still open; consider alternate genes or non-genetic diagnoses |
Say residual risk out loud with the assumptions: ethnicity prior used, detection rate, genes included, and whether a familial variant is known.
Why Negative Screening Is Not Zero
- Imperfect analytic/clinical sensitivity: A 95% detection screen leaves ~5% of carriers undetected before Bayes normalization.
- Limited gene set: A CFTR-only discussion does not clear risk for a phenotypically overlapping different gene.
- Variant-type blind spots: Some methods miss large deletions/duplications, deep intronic variants, or certain structural events unless del/dup or alternate assays are included.
- Wrong test for the family: Panel screening ≠ testing for a known familial pathogenic variant.
- Misassigned prior: Using a pan-ethnic prior when a high-risk ancestry prior applies understates pre-test risk and can distort residual counseling.
Teaching comparison: Prior 1/25, detection 95% → posterior ≈ 1/481 (Section 2.3). Counseling line: "Your chance of being a carrier is now about 1 in 480, not zero."
When to Offer Additional Testing
Offer or escalate testing when residual risk or clinical stakes remain material:
| Situation | Preferred next step | Rationale |
|---|---|---|
| Familial pathogenic variant known in relative | Site-specific testing for that variant | Screening panels can miss the family's variant or report it differently |
| High residual carrier risk + pregnancy plans | Partner carrier testing; consider diagnostic prenatal options if both high risk | Converts individual residual risk into couple risk |
| Negative targeted screen, ancestry or phenotype suggests broader risk | Expanded next-generation sequencing of the relevant gene(s), including del/dup as indicated | Improves detection beyond targeted variant lists |
| XL family, woman with intermediate posterior | Molecular carrier testing of the familial variant or full gene analysis per indication | Clinical/Bayes numbers guide urgency but genotyping clarifies |
| Affected proband never genotyped | Test the affected person first when available | Identifies the familial variant that makes relatives' testing definitive |
| Uninformative VUS-only results | Do not treat VUS as pathogenic; use phenotype, segregation, and lab reclassification pathways | Avoids mismanaging residual risk on uncertain variants |
Worked Couple Residual Risk
Consultand posterior carrier risk after negative screen ≈ 1/480. Partner untested with population carrier risk 1/25.
- Approximate couple both-carrier probability ≈ (1/480)×(1/25) = 1/12,000
- Affected-child risk ≈ (1/12,000)×(1/4) = 1/48,000
If the partner then screens negative with the same 95% detection and a 1/25 prior, his posterior is also ≈ 1/481. Couple affected risk ≈ (1/481)×(1/481)×(1/4) ≈ 1/926,000 (order-of-magnitude teaching). The plan may shift from "partner testing urgently" to "residual risk is very low; still offer education about limitations."
If the partner tests positive, the consultand's residual 1/480 suddenly matters: affected risk ≈ (1/480)×1×(1/4) = 1/1,920, and prenatal/diagnostic options should be reviewed.
Follow-Up Medical Plans Beyond the Laboratory
Residual-risk visits should produce a concrete plan:
- Who to test next (partner, affected relative, parents for phasing/de novo assessment).
- Which assay (site-specific, sequencing, del/dup, biochemical).
- Reproductive options if residual couple risk is unacceptable to the patient (CVS/amnio for known variants, IVF with PGT-M when a familial variant is characterized, donor gametes, adoption)—presented non-directively.
- Phenotype-first surveillance when genotype is uninformative but empiric risks remain (for example, cancer syndrome differentials with uninformative panels—coordinate with Domain 1C concepts).
- Cascade letters / relative contact when a pathogenic variant is found; residual-risk counseling for negatives in the cascade uses site-specific sensitivity near-ceiling, not population screening residuals.
- Recontact policy: detection rates and gene lists change; document that reinterpretation may alter residual risk.
Counseling Language That Matches Board Expectations
- Replace "You're negative, so you're fine" with "Your residual carrier risk is approximately X because the test detects about Y% of carriers."
- Separate assay limitation from patient identity—negative results are about test performance, not personal failure.
- For XL manifesting-carrier nuances or AR mild genotypes, clarify that residual risk discussions concern the defined phenotype in the stem.
- When numbers are tiny, still offer the option of partner testing if it would change decisions; autonomy includes declining further testing.
Integrating the Whole Domain 2A Sequence
| Step | Output |
|---|---|
| Pedigree construction | Who is at risk; inheritance hypothesis |
| Mendelian calculation | Prior risk by position |
| Bayesian update | Posterior given negative/positive conditional data |
| Residual risk + plan | Actionable next medical steps and reproductive counseling |
Exam vignettes often ask for the best next step rather than the fraction alone. If two answers both quote a plausible residual risk, choose the one that pairs the number with the correct assay and relative to test.
High-Yield Pitfalls
- Declaring zero risk after a negative expanded panel when an affected relative's variant remains untested or unknown
- Offering only reassurance when a partner is a known carrier and the consultand has nontrivial residual risk
- Using screening residual-risk math after a negative site-specific test for a known familial variant (those residuals are typically laboratory-quality discussions, not 1/480-style population Bayes)
- Ignoring consanguinity or shared ancestry that raises partner prior above population figures
- Forgetting to update the plan when an affected family member finally receives a molecular diagnosis
Residual risk is the counseling product patients remember. Make it numeric, assumption-transparent, and paired with a follow-up medical plan.
A client completes a negative carrier screen with 95% detection and a Bayesian residual carrier risk of about 1/480. Which counseling statement is most appropriate?
A pathogenic variant is identified in an affected sibling. The consultand previously had a negative general carrier screening panel for the same disease gene category. What is the best next testing step for the consultand?
After negative carrier screening, a consultand's residual carrier risk is 1/480 and the partner's untreated population carrier risk is 1/25. What is the approximate risk of an affected child before partner testing (AR model)?
Which follow-up plan element is most essential after quoting a nonzero residual risk?